<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>VEGF-A on Michael’s Domain</title><link>https://jeltsch.org/en/tags/vegf-a/</link><description>Recent content in VEGF-A on Michael’s Domain</description><generator>Hugo</generator><language>en-us</language><copyright>Copyright © 2002 - 2026 Michael Jeltsch.</copyright><lastBuildDate>Fri, 24 Jul 2026 00:18:18 +0300</lastBuildDate><atom:link href="https://jeltsch.org/en/tags/vegf-a/index.xml" rel="self" type="application/rss+xml"/><item><title>OMG: T. rex did not have VEGF-B!</title><link>https://jeltsch.org/en/omg_t_rex_did_not_have_vegf_b/</link><pubDate>Wed, 05 Apr 2023 00:00:00 +0000</pubDate><guid>https://jeltsch.org/en/omg_t_rex_did_not_have_vegf_b/</guid><description>&lt;p&gt;Our work on the evolutionary origin of the PDGF and VEGF growth factors has just been published in &lt;em&gt;Angiogenesis&lt;/em&gt;: 
 &lt;a href="https://doi.org/10.1007/s10456-023-09874-9" target="_blank" rel="noopener noreferrer nofollow"&gt;https://doi.org/10.1007/s10456-023-09874-9&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
. We analyzed both PDGFs and VEGFs, but our focus was naturally on the VEGF side of things. It&amp;rsquo;s just a coincidence that the PDGFs happened to be a subgroup of the VEGFs and not vice versa, but that&amp;rsquo;s of course just our biased point of view :-)Since we do lymphatic research, we can proudly announce that the phylogenetic oldest VEGF likely resembled VEGF-C and featured the enigmatic silk homology domain. It makes intuitive sense (and had been proposed before by Jörg Wilting), because the most simple vascular systems that we know of are the so-called hemolymph systems (e.g., in insects), which share many features with the lymphatic system.With this publication, we did not do something exceptional that only a few can do. We did something everybody could do but nobody had done so far: looking systematically at which animals have which PDGFs and VEGFs. Actually, we did something new: we developed a crowdsourcing method for classifying PDGFs and VEGFs. Instead of asking people, we asked databases. There are many PDGF-like and VEGF-like sequences in databases, which are only recognizable as such by the homology of their amino acid sequence. In order to know whether we are dealing, e.g., with a VEGF-C or a VEGF-D, we are running many (PSI)BLAST searches, and then we tally up the majority opinion (as determined by the top hits).Many surprises waited for us after the bioinformatics script had finished its job after two weeks of finding and comparing PDGF- and VEGF-like sequences:&lt;/p&gt;</description></item><item><title>A Nobel Prize for angiogenesis research?</title><link>https://jeltsch.org/en/a_nobel_prize_for_angiogenesis_research/</link><pubDate>Sun, 27 Oct 2013 00:00:00 +0000</pubDate><guid>https://jeltsch.org/en/a_nobel_prize_for_angiogenesis_research/</guid><description>&lt;p&gt;In 2008, during a dinner in Stockholm (when I participated in the Novo Nordisk Foundation 8th Annual Conference on Vascular Biology in Diabetes Complications) I proposed to 
 &lt;a href="http://ki.se/ki/jsp/polopoly.jsp?l=en&amp;amp;d=17273" target="_blank" rel="noopener noreferrer nofollow"&gt;Christer Betsholtz&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
 to award the Nobel Prize to the world-wide community of postdocs, which are the unsung heroes of today&amp;rsquo;s research. But the 
 &lt;a href="http://www.nobelprize.org/nobel_organizations/nobelfoundation/statutes.html" target="_blank" rel="noopener noreferrer nofollow"&gt;Statutes of the Nobel Foundation&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
 forbid to award the price to more than three people. However, statutes can be changed and the Nobel Foundation did exactly that 40 years ago when they stopped awarding the price to dead people. And in this changing world, less and less discoveries and inventions are made by individuals. But here&amp;rsquo;s my newest proposal, which adheres to the rule of maximally three: Kari Alitalo is probably the only Nobel Prize worthy researcher in the country where I work (Finland). Seriously: after 
 &lt;a href="http://en.wikipedia.org/wiki/Judah_Folkman" target="_blank" rel="noopener noreferrer nofollow"&gt;Judah Folkman&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
 has passed away, there are not many options to award the prize to somebody from the angiogenesis field. Judah Folkman was the father of the hypothesis, that all tumors should be treatable by anti-angiogenesis (
 &lt;a href="http://dx.doi.org/10.1056/NEJM197111182852108" target="_blank" rel="noopener noreferrer nofollow"&gt;Folkman J. Tumor Angiogenesis: Therapeutic Implications. New England Journal of Medicine. 1971;285(21):1182–6&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
). The Nobel Prize committee missed that chance. And because the field has already significantly contributed to the treatment of cancer (and arguably will still contribute much), it is not so far off to think of a shared prize for the discoverers of the VEGFs. VEGF was discovered more or less independently by several research groups around 25 years ago, among them 
 &lt;a href="http://en.wikipedia.org/wiki/Napoleone_Ferrara" target="_blank" rel="noopener noreferrer nofollow"&gt;Napoleone Ferrara&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
’s and 
 &lt;a href="http://cvbr.hms.harvard.edu/researchers/hdvorak.html" target="_blank" rel="noopener noreferrer nofollow"&gt;Harold Dvorak&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
’s. Most notably, Ferrara’s group at 
 &lt;a href="http://en.wikipedia.org/wiki/Genentech" target="_blank" rel="noopener noreferrer nofollow"&gt;Genentech&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
 continued the research most successfully until today resulting in the first antiangiogenic cancer drug in 2004. While the discovery of VEGF and the resulting angiogenesis research was not dependent on any single lab, the lymphangiogenesis field was essentially single-handedly re-invented and brought into the molecular era by 
 &lt;a href="http://en.wikipedia.org/wiki/Kari_Alitalo" target="_blank" rel="noopener noreferrer nofollow"&gt;Kari Alitalo&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
 in the years following 1995 - after it had become senile and was lingering without any significant progress since the 1960s. A shared prize to Ferrara, Dvorak and Alitalo? There is an 
 &lt;a href="http://www.avastin.com/patient" target="_blank" rel="noopener noreferrer nofollow"&gt;anti-VEGF-A cancer drug&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
 on the market and the only thing lacking is a successful anti- or pro-VEGF-C drug. Both are in clinical trials as of this writing (
 &lt;a href="http://clinicaltrials.gov/show/NCT01514123" target="_blank" rel="noopener noreferrer nofollow"&gt;anti-VEGF-C&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
, 
 &lt;a href="http://www.laurantis.com/products/lymfactin" target="_blank" rel="noopener noreferrer nofollow"&gt;pro-VEGF-C&amp;nbsp;






 
 
 
 &lt;svg class="svg-inline--fa fas fa-up-right-from-square fa-2xs" fill="currentColor" aria-hidden="true" role="img" viewBox="0 0 512 512" overflow="visible"&gt;&lt;use href="#fas-up-right-from-square"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/a&gt;
).&lt;/p&gt;</description></item></channel></rss>